Ann: Race releases complete cardio-protection data & video, page-67

Cardio Protection and Anti-Cancer;

My view on the Mechanism of Action of what is going on;

1. Bisantrene is a magnet to iron.

2. Cardiotoxicity is caused by iron dependent functions such as oxidative stress and ROS production.

3. By binding tightly to iron, Bisantrene reduces the iron that feeds Cardiotoxicity.

4. Basically, Bisantrene is the ‘Cookie Monster’ and iron is the ‘Cookie’. Without the cookie there is no cardiotoxicity.

5. But Oxidative stress can help kill cancer so reducing this can reduce anti-cancer effects.

6. Some good news, healthy cells counteract oxidative stress at a superior rates to cancer cells.

7. Whilst Oxidative stress is sufficiently reduced for healthy cells to be protected, cancer cells remain unprotected.

8. Bisantrene therefore hits the sweet spot where it retains cardio protection and anti-cancer effects.

9. At high doses Bisantrene acts relies on its Anthracycline effects to kill cancer.

10. At low doses Bisantrene is relies on its super power as an FTO inhibitor (binding to the catalytic pocket of FTO).

11. FTO overexpression correlates to the growth of 30+ cancers and also linked to drug resistance.

12. Reducing FTO expression can stop the growth of cancer and helps kill treatment resistance tumours.

13. Bisantrene is additive and synergenistic with other standard of care treatments.

There is definitely a lot of luck involved with Bisantrene. Starting off as a legacy chemo drug for AML. Now extending to a potential platform drug as the worlds first FTO inhibitor in the clinic and cardio-protective anti-cancer solution.

#Disrupting Cardio-oncology 2023